Reanalysis of the NCCN PD-L1 Companion Diagnostic Assay Study for Lung Cancer in the Context of PD-L1 Expression Findings in Triple-Negative Breast Cancer

Authors

David L. Rimm, Yale University
Gang Han, Texas A & M University - College Station
Janis M. Taube, Johns Hopkins University
Eunhee S. Yi, Mayo Clinic
Julia A. Bridge, University of Nebraska Medical CenterFollow
Douglas B. Flieder, Fox Chase Cancer Center
Robert Homer, Yale University
Anja C. Roden, Mayo Clinic
Fred R. Hirsch, University of Colorado Anschutz Medical Campus
Ignacio I. Wistuba, The University of Texas MD Anderson Cancer Center
Lajos Pusztai, Yale University

Document Type

Article

Journal Title

Breast cancer research : BCR

Publication Date

2019

Volume

21

Abstract

The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.

DOI Link

10.1186/s13058-019-1156-6

ISSN

1465-542X

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Rimm, David L.; Han, Gang; Taube, Janis M.; Yi, Eunhee S.; Bridge, Julia A.; Flieder, Douglas B.; Homer, Robert; Roden, Anja C.; Hirsch, Fred R.; Wistuba, Ignacio I.; and Pusztai, Lajos, "Reanalysis of the NCCN PD-L1 Companion Diagnostic Assay Study for Lung Cancer in the Context of PD-L1 Expression Findings in Triple-Negative Breast Cancer" (2019). Journal Articles: Pathology and Microbiology. 65.
https://digitalcommons.unmc.edu/com_pathmicro_articles/65